Know Cancer

forgot password

A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)

Phase 1
18 Years
Not Enrolling
Non-Small-Cell Lung Cancer

Thank you

Trial Information

A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)

Inclusion Criteria:

1. The subject has a confirmed histological diagnosis of NSCLC.

2. The subject has previously been treated with a platinum- or taxane-containing

3. The subject has stage IIIB NSCLC with malignant effusion, stage IV or recurrent NSCLC
that is not amenable to curative therapy (either surgery or radiation therapy).

4. The subject is at least 18 years old.

5. The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of

6. The subject has a life expectancy of ≥3 months.

7. The subject has adequate organ and marrow function.

8. The subject has cardiac-specific enzyme levels (creatine phosphokinase [CPK] total,
CPK-MB, and troponin) below the institution's ULN.

9. The subject is capable of understanding the protocol and has signed the informed
consent document.

10. Sexually active subjects (male and female) must use medically accepted methods of
contraception during the entire course of the study.

11. Female subjects of childbearing potential must have a negative pregnancy test at

12. If a subject has received more than three prior regimens of cytotoxic chemotherapy,
or more than two biological or targeted therapies, or more than 3000 cGy to >25% of
his or her bone marrow, the investigator must discuss with the sponsor regarding
subject suitability prior to enrollment.

13. The subject has had no other diagnosis of malignancy (unless non-melanoma skin
cancer, in situ carcinoma of the cervix, or a malignancy diagnosed ≥5 years ago, and
has had no evidence of disease for 5 years prior to screening for this study).

Exclusion Criteria:

1. The subject has received systemic anticancer therapy (eg, chemotherapy, biologic
therapy, targeted therapy, cytokines, or hormones) within 14 days before the first
dose of study drug.

2. The subject has received radiation to >25% of his or her bone marrow within 30 days
of XL999 treatment.

3. The subject has not recovered to Grade ≤1 from adverse events (AEs) due to
investigational or other agents administered more than 14 days prior to study

4. The subject has history of or known brain metastases, current spinal cord
compression, or carcinomatous meningitis.

5. The subject is known to be positive for the human immunodeficiency virus (HIV).

6. The subject has uncontrolled and/or intercurrent illness including but not limited to
the following:

1. Cardiac:

- Left ventricular ejection fraction (LVEF) assessed by 99mTc multiple-gated
acquisition scan (MUGA) is below the institution's lower limit of normal
(LLN) at screening. If regional wall motion abnormalities are noted on the
MUGA, cardiology consultation should be performed prior to enrollment.

- History of pulmonary hypertension.

- History of congestive heart failure (CHF) (New York Heart Association
[NYHA] Class II, III, or IV).

- Active or unstable ischemic disease, including angina pectoris, myocardial
infarction, coronary artery bypass grafting (CABG) within the past 12

- Electrocardiogram (ECG) showing signs of ischemia or myocardial, valvular,
or coronary artery disease unless deemed clinically insignificant by a

- Onset of any changes between the screening ECG and pre-dose ECG unless
deemed clinically insignificant by a cardiologist.

- ECG abnormalities that could cause interpretation difficulties after XL999
administration (eg, left bundle branch block [LBBB], atrial fibrillation,
A-V blocks, pacemakers, digoxin).

2. Vascular:

- Blood pressure >150/90 mm Hg despite antihypertensive therapy with two

- Cerebrovascular accident, transient ischemic attack, or evidence of active
peripheral vascular disease within 12 months prior to study enrollment.

3. Hematologic:

- National Cancer Institute Common Terminology Criteria for Adverse Events
(NCI CTCAE) v3.0 Grade ≥3 hemorrhage within 30 days of study enrollment.

- Evidence of bleeding diathesis or coagulopathy.

- Requirement for therapeutic anticoagulation. Patients receiving
anticoagulants (eg, warfarin, heparin) will be excluded if international
normalized ratio >1.5 or partial thromboplastin time (PTT) >1.5× the
institution's ULN.

4. Recent surgical procedures:

- Major surgery or open biopsy within 30 days of starting treatment with

- Anticipation of major surgical procedure during the study.

5. Wound healing problems:

- History of abdominal fistula, gastrointestinal perforation, or
intra-abdominal abscess within 30 days prior to treatment.

- Serious, non-healing wound, ulcer, or bone fracture.

6. Psychiatric illness that would limit compliance with study requirements.

7. The subject is pregnant or breastfeeding.

8. The subject has a known allergy or hypersensitivity to components of the XL999

9. The subject is unable or unwilling to abide by the study.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety, tolerability, and maximum tolerated dose of XL999 administered weekly as a 4-hour intravenous infusion

Outcome Time Frame:

Inclusion until 30 days post last treatment

Safety Issue:


Principal Investigator

Lynne A. Bui, MD

Investigator Role:

Study Director

Investigator Affiliation:

Exelixis, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

August 2007

Completion Date:

May 2008

Related Keywords:

  • Non-Small-Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



UCLA Medical CenterLos Angeles, California  90095-7059
Wayne State University, Karmanos Cancer InstituteDetroit, Michigan  
Hematology-Oncology Associates of RocklandNyack, New York  10956
Cancer Therapy and Research Center at The UT Health Science Center at San AntonioSan Antonio, Texas  78229
Peachtree Hematology Oncology ConsultantsAtlanta, Georgia  30309